Ferrer: Ferrer Advances Research into Progressive Supranuclear Palsy (PSP) with the Inclusion of the First Participant in a Phase II Clinical Trial

Ferrer, a B Corp-certified international pharmaceutical company, has announced the dosing of the first participant in the Phase II clinical trial, PROSPER. The study seeks to evaluate the safety a...